The biologic drug dupilumab (Dupixent) is now indicated for treatment of children 12 year and over with moderate-to- severe atopic dermatitis (AD), according to manufacturer Sanofi Genzyme. The company says the registration of dupilumab has been extended from adults to include patients aged 12-17 years. It is now seeking PBS listing for the biologic in ...
Dupilumab now available for treatment of children with atopic dermatitis.
By Michael Woodhead
25 Nov 2019